Harry Palmin
2017
In 2017, Harry Palmin earned a total compensation of $693.3K as Chief Financial Officer at Opexa Therapeutics.
Compensation breakdown
| Option Awards | $594,151 |
|---|---|
| Salary | $99,167 |
| Total | $693,318 |
Palmin received $594.2K in option awards, accounting for 86% of the total pay in 2017.
Palmin also received $99.2K in salary.
Rankings
In 2017, Harry Palmin's compensation ranked 10,654th out of 14,666 executives tracked by ExecPay. In other words, Palmin earned more than 27.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 10,654 out of 14,666 | 27th |
Division Manufacturing | 4,153 out of 5,768 | 28th |
Major group Chemicals And Allied Products | 1,478 out of 2,074 | 29th |
Industry group Drugs | 1,208 out of 1,730 | 30th |
Industry Pharmaceutical Preparations | 938 out of 1,329 | 29th |
Source: SEC filing on April 9, 2018.
Palmin's colleagues
We found four more compensation records of executives who worked with Harry Palmin at Opexa Therapeutics in 2017.
News
Opexa Therapeutics CEO Chris Schelling's 2022 pay jumps 51% to $834K
April 14, 2023
Opexa Therapeutics Chief Business Officer Jefferson Davis receives $635K in 2021
April 15, 2022
Opexa Therapeutics CEO Chris Schelling's 2020 pay falls 54% to $676K
April 16, 2021
Opexa Therapeutics CEO Chris Schelling's 2019 pay jumps 167% to $1.5M
October 14, 2020
Opexa Therapeutics CEO Chris Schelling's 2018 pay slips 6% to $550K
April 12, 2019